Zobrazeno 1 - 10
of 11
pro vyhledávání: '"HAYATO MIZUTA"'
Autor:
Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-16 (2024)
Abstract Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma
Externí odkaz:
https://doaj.org/article/2452462725da441b9de6e8ec14089d0a
Autor:
Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, Takuya Yoshimoto, Takashi Asakawa, Yasushi Yoshimura, Shigeki Yoshiura
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract Cancer cell resistance arises when tyrosine kinase inhibitor (TKI)-targeted therapies induce a drug-tolerant persister (DTP) state with growth via genetic aberrations, making DTP cells potential therapeutic targets. We screened an anti-cance
Externí odkaz:
https://doaj.org/article/8811aae012de4262bbd1be6fa86340ba
Autor:
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung c
Externí odkaz:
https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32
Autor:
BAYDOUN, HASSAN, YUJI KATO, HIROKI KAMO, HÜSCH, ANNA, HAYATO MIZUTA, RYOTA KAWAHARA, SIRO SIMIZU
Publikováno v:
Oncology Research; 2024, Vol. 32 Issue 4, p607-614, 8p
Publikováno v:
The FEBS journalReferences. 290(1)
C-mannosylation is a unique type of protein glycosylation via C-C linkage between an α-mannose and a tryptophan residue. This modification has been identified in about 30 proteins and regulates several functions, such as protein secretion and intrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f01dcbdfc8ffbdcb3351be0a46ce8215
https://pubmed.ncbi.nlm.nih.gov/35942636
https://pubmed.ncbi.nlm.nih.gov/35942636
Autor:
Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cédric Pobel, Ludovic Bigot, Olivier Déas, Juan-David Florez-Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet
Publikováno v:
Cancer Research. 83:3458-3458
Background Several selective FGFR inhibitors have been developed for the treatment of FGFR-driven urothelial cancer, in particular erdafitinib which received FDA and EMA approval. Molecular mechanisms responsible for resistance to FGFR inhibitors hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b01c496a3361e2e0e35c589e0a9262b
https://doi.org/10.1158/1538-7445.am2023-3458
https://doi.org/10.1158/1538-7445.am2023-3458
Autor:
Giorgia Guaitoli, Francesco Facchinetti, Juan David Flórez-Arango, Floriane Braye, Hayato Mizuta, Santiago Ponce-Aix, Damien Vasseur, Ken André Olaussen, Stefan Michiels, Mihaela Aldea, Jordi Remon, Fabrice Barlesi, Benjamin Besse, David Planchard, Luc Friboulet
Publikováno v:
Cancer Research. 83:3418-3418
Introduction: Advent of targeted therapies has deeply changed treatment of advanced oncogene-addicted non-small cell lung cancer (NSCLC), but development of resistance remains a main issue. Given the efficacy of next generation tyrosine kinase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a6f1becc59cba3c444d2caa0c85be26
https://doi.org/10.1158/1538-7445.am2023-3418
https://doi.org/10.1158/1538-7445.am2023-3418
Autor:
Takehiro Suzuki, Siro Simizu, Naoshi Dohmae, Kento Mori, Yoshiyuki Osada, Kazuki Miura, Hayato Mizuta
Publikováno v:
Biochimica et biophysica acta. General subjects. 1864(9)
Background C-mannosylation is the one of glycosylations. Microfibril-associated glycoprotein 4 (MFAP4), an important protein for tissue homeostasis and cell adhesion, contains a consensus sequence of C-mannosylation in its fibrinogen C-terminal domai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8aa3a9e7066c4155a89089f473ff501
https://pubmed.ncbi.nlm.nih.gov/32442478
https://pubmed.ncbi.nlm.nih.gov/32442478
Publikováno v:
International Journal of Oncology.
R‑spondin2 (Rspo2), one of the four members of the R‑spondin family of proteins, has agonistic activity in the Wnt/β‑catenin signaling pathway, and it is associated with normal development, as well as disease, such as cancer. The present study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040b31d7663dd37b13c7710070f1b9e6
https://doi.org/10.3892/ijo.2019.4767
https://doi.org/10.3892/ijo.2019.4767
Autor:
Siro Simizu, Kazuki Miura, Takehiro Suzuki, Hongkai Sun, Naoshi Dohmae, Haruka Takada, Yudai Ishizawa, Hayato Mizuta
Publikováno v:
Biochimica et Biophysica Acta (BBA) - General Subjects. 1865:129833
Background C-mannosylation is a unique type of glycosylation. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) is a multidomain extracellular metalloproteinase that contains several potential C-mannosylation sites. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a989bb9b5abcd2eb7c1bb201fef163
https://doi.org/10.1016/j.bbagen.2020.129833
https://doi.org/10.1016/j.bbagen.2020.129833